image header

Investor Overview

Investor Overview

We are a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. Our lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept is currently in multiple Phase 1 and 2 clinical trials and has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer antibodies. ALX Oncology is currently focusing on combining evorpacept with anti-cancer antibodies, antibody-drug conjugates, and PD-1/PD-L1 immune checkpoint inhibitors. Our strategy is to pursue evorpacept as a potentially critical component of future oncology combination treatments.

ALX Oncology

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

May 9, 2024

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update Read more

May 7, 2024

ALX Oncology Appoints Allison Dillon as Chief Business Officer Read more

Apr 30, 2024

ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer Read more

Upcoming Events
There are no upcoming events scheduled at this time.